Literature DB >> 14973524

Patterns of use of sildenafil among commercially insured adults in the United States: 1998-2002.

T Delate1, V A Simmons, B R Motheral.   

Abstract

Sildenafil is increasingly being marketed to younger healthcare consumers. The purpose of this study was to profile sildenafil use in commercially insured, adult beneficiaries. Annual ambulatory prescription claims data from 1998 to 2002, for a nationwide, random sample of over 5 million life-years of commercially insured adults (aged > or =18 y), were examined retrospectively. The overall prevalence of sildenafil use increased from 0.8% (1998) to 1.4% (2002), an 84% increase. While the growth in use slowed in older males, use became more pronounced in younger males and females and decreased in older females. The fastest growing segment of users was found to be males aged 18-45 y. The proportion of users who had two or more claims for a medication that is suspected of inducing erectile dysfunction (ED) and/or a marker for a suspected ED-inducing disease decreased over the study period. Our findings suggest that use may increase among younger male and female patients and those without an underlying etiologic reason for use.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14973524     DOI: 10.1038/sj.ijir.3901191

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  7 in total

1.  Recreational use of erectile dysfunction medications in undergraduate men in the United States: characteristics and associated risk factors.

Authors:  Christopher B Harte; Cindy M Meston
Journal:  Arch Sex Behav       Date:  2010-04-01

2.  Sexually transmitted diseases among users of erectile dysfunction drugs: analysis of claims data.

Authors:  Anupam B Jena; Dana P Goldman; Amee Kamdar; Darius N Lakdawalla; Yang Lu
Journal:  Ann Intern Med       Date:  2010-07-06       Impact factor: 25.391

3.  Data on the utilization of treatment modalities for ED in Taiwan in the era of PDE5 inhibitors.

Authors:  W-K Tsai; B-P Jiann
Journal:  Int J Impot Res       Date:  2014-01-23       Impact factor: 2.896

4.  Rewarding properties of sildenafil citrate in mice: role of the nitric oxide-cyclic GMP pathway.

Authors:  Pouya Tahsili-Fahadan; Noushin Yahyavi-Firouz-Abadi; Amir Hossein Orandi; Behnaz Esmaeili; Zahra Basseda; Ahmad Reza Dehpour
Journal:  Psychopharmacology (Berl)       Date:  2006-01-20       Impact factor: 4.530

5.  Bigger and better: how Pfizer redefined erectile dysfunction.

Authors:  Joel Lexchin
Journal:  PLoS Med       Date:  2006-04-11       Impact factor: 11.069

6.  Sildenafil and suicide in Sweden.

Authors:  Ralph Catalano; Sidra Goldman-Mellor; Tim A Bruckner; Terry Hartig
Journal:  Eur J Epidemiol       Date:  2021-04-01       Impact factor: 8.082

7.  Sociodemographic patterns in pharmacy dispensing of medications for erectile dysfunction in Sweden.

Authors:  Pernilla J Bjerkeli; Shai Mulinari; Sofia Zettermark; Juan Merlo
Journal:  Eur J Clin Pharmacol       Date:  2017-11-03       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.